Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson’s Disease: A Case Report

by Gianluca Trifirò, Ilaria Marcianò, Paola M. Cutroneo, Edoardo Spina, Eliana Mirabelli, Costantino J. Trombetta, Francesca Morgante, Francesca Morgante
Published 2018-06-01

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study

by Ylenia Ingrasciotta, Viviana Lacava, Ilaria Marcianò, Francesco Giorgianni, Giovanni Tripepi, Graziella D’ Arrigo, Alessandro Chinellato, Daniele Ugo Tari, Domenico Santoro, Gianluca Trifirò
Published 2019-09-01

Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study

by Ylenia Ingrasciotta, Viviana Lacava, Ilaria Marcianò, Francesco Giorgianni, Giovanni Tripepi, Graziella D’. Arrigo, Alessandro Chinellato, Daniele Ugo Tari, Domenico Santoro, Gianluca Trifirò
Published 2020-07-01

Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients:...

by Ylenia Ingrasciotta, Francesco Giorgianni, Ilaria Marcianò, Jenny Bolcato, Roberta Pirolo, Alessandro Chinellato, Valentina Ientile, Domenico Santoro, Armando A Genazzani, Angela Alibrandi, Andrea Fontana, Achille P Caputi, Gianluca Trifirò
Published 2016-01-01

Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014

by Ilaria Marcianò, Ylenia Ingrasciotta, Francesco Giorgianni, Valentina Ientile, Alessandro Chinellato, Daniele Ugo Tari, Rosa Gini, Salvatore Cannavò, Maurizio Pastorello, Salvatore Scondotto, Pasquale Cananzi, Giuseppe Traversa, Francesco Trotta, Valeria Belleudi, Antonio Addis, Gianluca Trifirò, Gianluca Trifirò, Gianluca Trifirò
Published 2018-03-01